Remus Pharmaceuticals Ltd
Remus Pharmaceuticals Q2 Results 2026 (FY27): Revenue ₹62.08 Cr, PAT ₹18.81 Cr
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Guidance rank: #33 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Remus Pharmaceuticals Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Standalone Revenue (H1 FY27 vs H1 FY26): ₹62.08 Cr vs ₹46.85 Cr, growth of 32.51%. EBITDA for H1 FY27: ₹21.70 Cr, up 46.92% YoY from ₹14.77 Cr in H1 FY26 (Standalone).
From Remus Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
How did Remus Pharmaceuticals' revenue grow in the September 2026 quarter?
- Standalone Revenue (H1 FY27 vs H1 FY26): ₹62.08 Cr vs ₹46.85 Cr, growth of 32.51%
- Standalone Revenue (H1 FY27 vs H2 FY26): ₹62.08 Cr vs ₹47.14 Cr, growth of 31.69%
- Consolidated Revenue (H1 FY27 vs H1 FY26): ₹614.12 Cr vs ₹400.20 Cr, growth of 53.45%
2 more points from Remus Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
What happened to Remus Pharmaceuticals' margins in Q2 FY27?
See what Remus Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
What capex is Remus Pharmaceuticals planning?
2 more points from Remus Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Remus Pharmaceuticals raising money or cutting debt?
See what Remus Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Remus Pharmaceuticals' order book?
See what Remus Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Continue your research
What Remus Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Amrutanjan Healt (Q2 FY27)
Q2 FY27 Net Sales:** ₹135.18 Crores, up 14.85% YoY (₹117.70 Crores in Q2 FY26) . Key investor presentation takeaways from Amrutanjan Health Care Ltd's Q2 FY27 i
- Pfizer (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹726.86 crore (Page 3). Key results statement takeaways from Pfizer Ltd's Q2 FY27 results stat
- Aarti Drugs (Q2 FY27)
826.2 Crore, up 27% YoY from Rs. Key investor presentation takeaways from Aarti Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peer
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Remus Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Remus Pharmaceuticals Ltd Q2 FY27 results?
Standalone Revenue (H1 FY27 vs H1 FY26): ₹62.08 Cr vs ₹46.85 Cr, growth of 32.51%. EBITDA for H1 FY27: ₹21.70 Cr, up 46.92% YoY from ₹14.77 Cr in H1 FY26 (Standalone).
What is Remus Pharmaceuticals Ltd share price analysis?
Remus Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 26.9 with a market cap of ₹997 Cr. Investors should review the full earnings analysis for detailed insights.
Is Remus Pharmaceuticals Ltd planning capital expenditure?
The results statement mentions the following capex, capacity expansion, or new plant/project details:.
Keep Remus Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.